BioLife Solutions Inc
NASDAQ:BLFS
BioLife Solutions Inc
PP&E Gross
BioLife Solutions Inc
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
BioLife Solutions Inc
NASDAQ:BLFS
|
PP&E Gross
$43m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
47%
|
CAGR 10-Years
41%
|
||
Haemonetics Corp
NYSE:HAE
|
PP&E Gross
$300.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
ICU Medical Inc
NASDAQ:ICUI
|
PP&E Gross
$658.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
22%
|
||
Align Technology Inc
NASDAQ:ALGN
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Lantheus Holdings Inc
NASDAQ:LNTH
|
PP&E Gross
$208.9m
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
||
Merit Medical Systems Inc
NASDAQ:MMSI
|
PP&E Gross
$458.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
BioLife Solutions Inc
Glance View
BioLife Solutions Inc., hailing from Bothell, Washington, tells a story of innovation within the niche yet critical biopreservation industry. Emerging as a vital player for cell and gene therapy developers, BioLife Solutions specializes in creating hypothermic storage and transport media tailored for fragile biologic material. Their cornerstone products, like CryoStor and HypoThermosol, are formulated to prolong the shelf-life and viability of cells, tissues, and organs during storage and transportation. These solutions are designed for ultra-cold environments, ensuring the cellular integrity required by biopharmaceutical companies and research institutions engaged in the leading-edge development of regenerative medicine. The company's business model is centered around both direct sales and strategic partnerships. By deeply embedding its proprietary preservation media into clinical-grade processes, BioLife Solutions establishes itself as an integral component of its clients' supply chains. In doing so, the company generates revenue not just from initial sales of its products, but from ongoing usage as therapies move through development pipelines into mainstream clinical applications. Additionally, their diversification into automated thawing devices and personalized medicine services bolster recurring revenue streams, positioning them strategically in an expanding market driven by technological advancements in cellular therapies. Thus, BioLife Solutions stands firmly at the confluence of innovation and necessity, drawing strength from its strategic foresight and commitment to preserving the future of medicine.
See Also
What is BioLife Solutions Inc's PP&E Gross?
PP&E Gross
43m
USD
Based on the financial report for Sep 30, 2024, BioLife Solutions Inc's PP&E Gross amounts to 43m USD.
What is BioLife Solutions Inc's PP&E Gross growth rate?
PP&E Gross CAGR 10Y
41%
Over the last year, the PP&E Gross growth was 5%. The average annual PP&E Gross growth rates for BioLife Solutions Inc have been -2% over the past three years , 47% over the past five years , and 41% over the past ten years .